Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
0.443 USD | +1.05% | +3.89% | -10.00% |
04-30 | Akili, Inc. Plans to Continue to Pursue Marketing Authorization from the U.S. Food and Drug Administration for Its EndeavorOTC Product | CI |
04-30 | Akili, Inc. to Reduce Workforce | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration1st Jan change | Capi. | |
---|---|---|
-10.00% | 34.46M | |
+11.11% | 225B | |
+10.92% | 186B | |
+13.22% | 135B | |
+26.15% | 107B | |
+0.91% | 63.56B | |
+6.74% | 51.32B | |
+12.37% | 51.04B | |
+8.03% | 43.3B | |
+4.88% | 36.99B |
- Stock Market
- Equities
- AKLI Stock
- News Akili, Inc.
- Morgan Stanley Adjusts Price Target on Akili to $3 From $2, Maintains Equal-Weight Rating